NYSEAMERICAN:PTN - Palatin Technologies Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.16 -0.02 (-1.69 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$1.16
Today's Range$1.16 - $1.21
52-Week Range$0.34 - $1.59
Volume804,655 shs
Average Volume1.85 million shs
Market Capitalization$184.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.83

About Palatin Technologies (NYSEAMERICAN:PTN)

Palatin Technologies logoPalatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include melanocortin peptide system program, including PL-8177 is a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, is a preclinical development candidate for treating ocular inflammation. In addition, the company develops natriuretic peptide system programs, including PL­3994, a natriuretic peptide receptor-A agonist for treatment of cardiovascular indications; and PL-5028, s dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Receive PTN News and Ratings via Email

Sign-up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:PTN
CUSIPN/A
Phone+1-609-4952200

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins28.55%
Return on Equity155.80%
Return on Assets27.77%

Miscellaneous

EmployeesN/A
Outstanding Shares198,680,000

Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions

What is Palatin Technologies' stock symbol?

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) released its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported $0.00 EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.04. The biopharmaceutical company had revenue of $8.96 million for the quarter. Palatin Technologies had a return on equity of 155.80% and a net margin of 28.55%. View Palatin Technologies' Earnings History.

What price target have analysts set for PTN?

3 Wall Street analysts have issued twelve-month price targets for Palatin Technologies' stock. Their forecasts range from $2.00 to $6.00. On average, they anticipate Palatin Technologies' stock price to reach $4.3333 in the next year. View Analyst Ratings for Palatin Technologies.

Are investors shorting Palatin Technologies?

Palatin Technologies saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 13,588,252 shares, an increase of 4.5% from the April 30th total of 13,008,196 shares. Based on an average daily volume of 1,677,900 shares, the days-to-cover ratio is currently 8.1 days. Approximately 7.2% of the company's shares are short sold.

Who are some of Palatin Technologies' key competitors?

Who are Palatin Technologies' key executives?

Palatin Technologies' management team includes the folowing people:
  • Dr. John K. A. Prendergast, Co-Founder & Non-Exec. Chairman (Age 64)
  • Dr. Carl Spana Ph.D., Co-Founder, Pres, CEO & Director (Age 56)
  • Mr. Stephen T. Wills CPA, MST, CFO, COO, Principal Accounting Officer, executive VP, Treasurer & Sec. (Age 61)
  • Burns McClellan, VP of Investor Relations
  • Dr. Johna Lucas M.A., M.D., F.A.C.O.G., Chief Medical Officer

Has Palatin Technologies been receiving favorable news coverage?

Press coverage about PTN stock has been trending somewhat positive on Saturday, according to Accern. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Palatin Technologies earned a news sentiment score of 0.06 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 44.36 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Palatin Technologies' major shareholders?

Palatin Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Tibra Equities Europe Ltd (0.20%), Northern Trust Corp (0.17%), Element Capital Management LLC (0.11%) and Citadel Advisors LLC (0.09%). View Institutional Ownership Trends for Palatin Technologies.

Which major investors are buying Palatin Technologies stock?

PTN stock was acquired by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd, Element Capital Management LLC, Citadel Advisors LLC and Northern Trust Corp. View Insider Buying and Selling for Palatin Technologies.

How do I buy shares of Palatin Technologies?

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Palatin Technologies' stock price today?

One share of PTN stock can currently be purchased for approximately $1.16.

How big of a company is Palatin Technologies?

Palatin Technologies has a market capitalization of $184.13 million.

How can I contact Palatin Technologies?

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.


MarketBeat Community Rating for Palatin Technologies (PTN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  204 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about Palatin Technologies and other stocks. Vote "Outperform" if you believe PTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Palatin Technologies (NYSEAMERICAN:PTN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Palatin Technologies in the last 12 months. Their average twelve-month price target is $4.3333, suggesting that the stock has a possible upside of 273.56%. The high price target for PTN is $6.00 and the low price target for PTN is $2.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.3333$4.3333$4.00$4.00
Price Target Upside: 273.56% upside261.11% upside422.74% upside422.74% upside

Palatin Technologies (NYSEAMERICAN:PTN) Consensus Price Target History

Price Target History for Palatin Technologies (NYSEAMERICAN:PTN)

Palatin Technologies (NYSEAMERICAN:PTN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/15/2018HC WainwrightSet Price TargetBuy$5.00View Rating Details
11/13/2017Canaccord GenuitySet Price TargetBuy$6.00View Rating Details
10/29/2017Roth CapitalSet Price TargetBuy$2.00View Rating Details
9/22/2016S&P Equity ResearchLower Price Target$0.61 ➝ $0.55View Rating Details
(Data available from 5/26/2016 forward)

Earnings

Palatin Technologies (NYSEAMERICAN:PTN) Earnings History and Estimates Chart

Earnings by Quarter for Palatin Technologies (NYSEAMERICAN:PTN)

Palatin Technologies (NYSEAMERICAN PTN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2018Q3($0.04)($0.0040)$8.96 millionViewListenView Earnings Details
2/12/2018Q2 18($0.18)$0.01$10.61 millionViewListenView Earnings Details
11/13/2017Q1 18$0.06$0.05$28.00 million$26.94 millionViewN/AView Earnings Details
9/25/2017Q4 17($0.02)$0.07$18.54 million$33.90 millionViewN/AView Earnings Details
5/18/2017Q3 2017$0.10($0.02)$60.00 million$10.82 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.07)($0.06)ViewListenView Earnings Details
11/15/2016Q117($0.08)($0.08)ViewN/AView Earnings Details
9/20/2016Q416($0.08)($0.09)ViewListenView Earnings Details
5/17/2016Q316($0.08)($0.08)ViewN/AView Earnings Details
2/16/2016Q216($0.07)($0.08)ViewN/AView Earnings Details
11/12/2015Q116($0.08)($0.08)ViewListenView Earnings Details
9/21/2015Q415($0.06)($0.09)$2.05 million$12.95 millionViewListenView Earnings Details
5/13/2015Q315($0.04)($0.07)$0.41 millionViewListenView Earnings Details
2/13/2015Q115$0.01$0.03$5.40 million$4.90 millionViewN/AView Earnings Details
11/18/2014Q1 15$0.04$0.01$9.00 million$4.93 millionViewN/AView Earnings Details
9/9/2014Q4 14$0.03($0.04)ViewN/AView Earnings Details
5/13/2014Q3($0.03)($0.01)$500.00 millionViewListenView Earnings Details
2/18/2014Q2 2014($0.04)($0.03)ViewN/AView Earnings Details
11/14/2013Q1($0.05)($0.04)ViewListenView Earnings Details
10/1/2013Q413($0.05)($0.04)ViewListenView Earnings Details
5/14/2013Q3 2013($0.05)($0.04)$0.0240 millionViewListenView Earnings Details
2/14/2013Q2 2013$0.01($0.02)ViewN/AView Earnings Details
11/14/2012Q1 2013($0.16)($0.09)ViewN/AView Earnings Details
9/11/2012Q4 2012($0.10)($0.14)ViewN/AView Earnings Details
5/14/2012Q3 2012($0.13)($0.17)ViewN/AView Earnings Details
2/15/2012Q2 2012($0.09)($0.08)ViewN/AView Earnings Details
11/15/2011Q1 2012($0.10)($0.10)ViewN/AView Earnings Details
9/22/2011Q4 2011($0.08)($0.13)ViewN/AView Earnings Details
5/16/2011Q3 2011($0.11)ViewN/AView Earnings Details
2/15/2011Q2 2011($0.09)ViewN/AView Earnings Details
11/15/2010Q1 2011($0.39)ViewN/AView Earnings Details
9/27/2010Q4 2010($3.95)ViewN/AView Earnings Details
5/13/2010Q3 2010($0.20)ViewN/AView Earnings Details
2/16/2010Q2 2010$0.44ViewN/AView Earnings Details
9/8/2009Q4 2009($0.02)ViewN/AView Earnings Details
5/15/2009Q3 2009$0.20$0.01ViewN/AView Earnings Details
2/17/2009Q2 2009$0.20($0.04)ViewN/AView Earnings Details
11/17/2008Q1 2009($0.50)ViewN/AView Earnings Details
9/30/2008Q4 2008($0.60)ViewN/AView Earnings Details
5/13/2008Q3 2008($0.40)($0.60)ViewN/AView Earnings Details
2/8/2008Q2 2008($1.00)($0.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Palatin Technologies (NYSEAMERICAN:PTN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Palatin Technologies (NYSEAMERICAN PTN) Insider Trading and Institutional Ownership History

Insider Trading History for Palatin Technologies (NYSEAMERICAN:PTN)
Institutional Ownership by Quarter for Palatin Technologies (NYSEAMERICAN:PTN)

Palatin Technologies (NYSEAMERICAN PTN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/4/2015Joseph Stanley HullDirectorBuy2,500$0.66$1,650.0021,500View SEC Filing  
10/2/2015Robert K Deveer JrDirectorBuy10,000$0.82$8,200.00222,393View SEC Filing  
2/26/2014Bvf Partners L P/IlMajor ShareholderSell540,181$1.14$615,806.34View SEC Filing  
2/19/2014Bvf Partners L P/IlMajor ShareholderSell305,966$1.17$357,980.22View SEC Filing  
3/19/2013Alan W DuntonDirectorBuy1,000$0.58$580.00View SEC Filing  
2/1/2013Alan W DuntonDirectorBuy2,000$0.59$1,180.00View SEC Filing  
1/28/2013Robert I TaberDirectorBuy5,000$0.59$2,950.00View SEC Filing  
12/31/2012Carl SpanaCEOBuy10,000$0.57$5,700.00View SEC Filing  
12/28/2012Stephen T WillsCFOBuy10,000$0.56$5,600.00View SEC Filing  
12/24/2012Perry B MolinoffDirectorBuy10,000$0.61$6,100.00View SEC Filing  
12/14/2012Robert K Deveer JrDirectorBuy21,960$0.70$15,372.00View SEC Filing  
9/4/2012Alan W DuntonDirectorBuy1,000$0.58$580.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Palatin Technologies (NYSEAMERICAN PTN) News Headlines

Source:
DateHeadline
Palatin Technologies, Inc. (PTN) Sees Significant Growth in Short InterestPalatin Technologies, Inc. (PTN) Sees Significant Growth in Short Interest
www.americanbankingnews.com - May 24 at 5:50 PM
HC Wainwright Analysts Give Palatin Technologies (PTN) a $5.00 Price TargetHC Wainwright Analysts Give Palatin Technologies (PTN) a $5.00 Price Target
www.americanbankingnews.com - May 15 at 1:43 PM
Palatin Technologies (PTN) Posts  Earnings Results, Beats Expectations By $0.04 EPSPalatin Technologies (PTN) Posts Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - May 15 at 11:39 AM
Palatin Tech revenues down 17%; net loss improves in Q1Palatin Tech revenues down 17%; net loss improves in Q1
seekingalpha.com - May 15 at 10:30 AM
An Intrinsic Calculation For Palatin Technologies Inc (NYSEMKT:PTN) Shows It’s 43% UndervaluedAn Intrinsic Calculation For Palatin Technologies Inc (NYSEMKT:PTN) Shows It’s 43% Undervalued
finance.yahoo.com - May 15 at 10:30 AM
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018
finance.yahoo.com - May 15 at 10:30 AM
Palatin Technologies (PTN) Scheduled to Post Quarterly Earnings on TuesdayPalatin Technologies (PTN) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 12 at 8:50 PM
Short Interest in Palatin Technologies, Inc. (PTN) Rises By 21.2%Short Interest in Palatin Technologies, Inc. (PTN) Rises By 21.2%
www.americanbankingnews.com - May 9 at 5:25 PM
Palatin Technologies Presents Positive Preclinical MC1 Receptor Agonist Data at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, MassachusettsPalatin Technologies Presents Positive Preclinical MC1 Receptor Agonist Data at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts
finance.yahoo.com - May 9 at 9:54 AM
Short Interest in Palatin Technologies, Inc. (PTN) Increases By 115.6%Short Interest in Palatin Technologies, Inc. (PTN) Increases By 115.6%
www.americanbankingnews.com - April 24 at 7:00 PM
Palatin Technologies (PTN) Enters $25 Million Equity Distribution AgreementPalatin Technologies (PTN) Enters $25 Million Equity Distribution Agreement
www.streetinsider.com - April 23 at 9:58 AM
Short Interest in Palatin Technologies, Inc. (PTN) Drops By 1.3%Short Interest in Palatin Technologies, Inc. (PTN) Drops By 1.3%
www.americanbankingnews.com - April 11 at 1:41 AM
HC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly FivefoldHC Wainwright: Why The Upside Potential For Palatin Technologies Is Nearly Fivefold
finance.yahoo.com - April 7 at 5:32 PM
HC Wainwright Begins Coverage on Palatin Technologies (PTN)HC Wainwright Begins Coverage on Palatin Technologies (PTN)
www.americanbankingnews.com - April 6 at 10:47 AM
Palatin Technologies (PTN) Given a $2.00 Price Target at Roth CapitalPalatin Technologies (PTN) Given a $2.00 Price Target at Roth Capital
www.americanbankingnews.com - April 4 at 3:32 PM
Palatin Technologies (PTN) Raised to C- at TheStreetPalatin Technologies (PTN) Raised to C- at TheStreet
www.americanbankingnews.com - April 3 at 10:40 AM
Palatin Technologies Presents Preclinical Oral Formulation Data on PL-8177, An Investigational Melanocortin Receptor 1 Agonist for Inflammatory Bowel DiseasesPalatin Technologies Presents Preclinical Oral Formulation Data on PL-8177, An Investigational Melanocortin Receptor 1 Agonist for Inflammatory Bowel Diseases
www.prnewswire.com - April 3 at 7:51 AM
With An ROE Of 242.93%, Has Palatin Technologies Inc’s (NYSEMKT:PTN) Management Done Well?With An ROE Of 242.93%, Has Palatin Technologies Inc’s (NYSEMKT:PTN) Management Done Well?
finance.yahoo.com - March 29 at 10:15 AM
Does Poltronic SA.’s (WSE:PTN) PE Ratio Warrant A Buy?Does Poltronic SA.’s (WSE:PTN) PE Ratio Warrant A Buy?
finance.yahoo.com - March 29 at 10:15 AM
Palatin Technologies, Inc. (PTN) Short Interest Down 3.9% in MarchPalatin Technologies, Inc. (PTN) Short Interest Down 3.9% in March
www.americanbankingnews.com - March 27 at 1:26 AM
Palatin Technologies (PTN) Anounces Submission of Bremelanotide NDA to FDA for Treatment of HSDD in Premenopausal WomenPalatin Technologies (PTN) Anounces Submission of Bremelanotide NDA to FDA for Treatment of HSDD in Premenopausal Women
www.streetinsider.com - March 26 at 4:18 PM
Does Palatin Technologies Inc’s (NYSEMKT:PTN) PE Ratio Signal A Buying Opportunity?Does Palatin Technologies Inc’s (NYSEMKT:PTN) PE Ratio Signal A Buying Opportunity?
finance.yahoo.com - March 22 at 9:44 AM
Palatin Technologies, Inc. (PTN) Short Interest UpdatePalatin Technologies, Inc. (PTN) Short Interest Update
www.americanbankingnews.com - March 10 at 2:52 AM
Palatin Technologies, Inc. (PTN) Sees Large Drop in Short InterestPalatin Technologies, Inc. (PTN) Sees Large Drop in Short Interest
www.americanbankingnews.com - February 28 at 1:56 AM
A Look at AMAG Pharmaceuticals’ CollaborationsA Look at AMAG Pharmaceuticals’ Collaborations
finance.yahoo.com - February 16 at 4:13 PM
Palatin Technologies (PTN) Posts  Earnings ResultsPalatin Technologies (PTN) Posts Earnings Results
www.americanbankingnews.com - February 13 at 11:12 AM
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018
www.prnewswire.com - February 12 at 7:43 AM
Short Interest in Palatin Technologies, Inc. (PTN) Declines By 6.6%Short Interest in Palatin Technologies, Inc. (PTN) Declines By 6.6%
www.americanbankingnews.com - February 9 at 6:36 PM
Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018
finance.yahoo.com - February 8 at 5:54 AM
Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational ... - PR Newswire (press release)Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational ... - PR Newswire (press release)
www.prnewswire.com - February 7 at 6:10 AM
Palatin Technologies Announces First Dosing In Phase 1 Study Of PL-8177Palatin Technologies Announces First Dosing In Phase 1 Study Of PL-8177
www.nasdaq.com - February 5 at 3:20 PM
Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 AgonistPalatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 Agonist
finance.yahoo.com - February 5 at 3:20 PM
Palatin Technologies, Inc. (PTN) Sees Significant Increase in Short InterestPalatin Technologies, Inc. (PTN) Sees Significant Increase in Short Interest
www.americanbankingnews.com - January 10 at 6:04 PM
Palatin Technologies, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for PL-8177 For ... - PR Newswire (press release)Palatin Technologies, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for PL-8177 For ... - PR Newswire (press release)
www.prnewswire.com - January 4 at 10:13 AM
Palatin Technologies, Inc. (PTN) Short Interest Up 53.4% in NovemberPalatin Technologies, Inc. (PTN) Short Interest Up 53.4% in November
www.americanbankingnews.com - December 11 at 8:36 PM
Technical Perspectives on Palatin Technologies, Atossa Genetics, DBV Technologies, and IDEXX Labs - PR Newswire (press release)Technical Perspectives on Palatin Technologies, Atossa Genetics, DBV Technologies, and IDEXX Labs - PR Newswire (press release)
www.prnewswire.com - December 11 at 11:00 AM
Short Interest in Palatin Technologies, Inc. (PTN) Rises By 1.0%Short Interest in Palatin Technologies, Inc. (PTN) Rises By 1.0%
www.americanbankingnews.com - November 28 at 1:04 AM

SEC Filings

Palatin Technologies (NYSEAMERICAN:PTN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Palatin Technologies (NYSEAMERICAN:PTN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Palatin Technologies (NYSEAMERICAN PTN) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.